Evidence map›Paper›PMID 34573762›Full record

ArticleEntropy (Basel, Switzerland)2021

The Complex Structure of the Pharmacological Drug-Disease Network.

Irene López-Rodríguez, Cesár F Reyes-Manzano, Ariel Guzmán-Vargas, Lev Guzmán-Vargas

Open access · goldAbstract read
In one paragraph

Article in Entropy (Basel, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.5field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Irene López-RodríguezLaboratorio de Sistemas Complejos, Unidad Interdisciplinaria en Ingeniería y Tecnologías Avanzadas, Instituto Politécnico Nacional, Av. IPN No. 2580, L. Ticomán, Ciudad de México 07340, Mexico.ORCID 0000-0003-0783-107X
Cesár F Reyes-ManzanoTecnológico Nacional de México, Tecnológico de Estudios Superiores de Ixtapaluca, Km. 7 Carretera Ixtapaluca-Coatepec S/N San Juan, Ixtapaluca, Estado de Mexico 56580, Mexico.ORCID 0000-0001-6543-8810
Ariel Guzmán-VargasLaboratorio de Investigación en Materiales Porosos, Instituto Politécnico Nacional-ESIQIE, Catálisis Ambiental y Química Fina, UPALM, Edificio 7 P. B., Zacatenco, C. P., Ciudad de México 07738, Mexico.ORCID 0000-0002-2213-1242
Lev Guzmán-VargasLaboratorio de Sistemas Complejos, Unidad Interdisciplinaria en Ingeniería y Tecnologías Avanzadas, Instituto Politécnico Nacional, Av. IPN No. 2580, L. Ticomán, Ciudad de México 07340, Mexico.ORCID 0000-0003-3098-8796
Instituto Politécnico Nacional · MXUniversidad México Contemporáneo · MX

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The complexity of drug-disease interactions is a process that has been explained in terms of the need for new drugs and the increasing cost of drug development, among other factors. Over the last years, diverse approaches have been explored to understand drug-disease relationships. Here, we construct a bipartite graph in terms of active ingredients and diseases based on thoroughly classified data from a recognized pharmacological website. We find that the connectivities between drugs (outgoing links) and diseases (incoming links) follow approximately a stretched-exponential function with different fitting parameters; for drugs, it is between exponential and power law functions, while for diseases, the behavior is purely exponential. The network projections, onto either drugs or diseases, reveal that the co-ocurrence of drugs (diseases) in common target diseases (drugs) lead to the appearance of connected components, which varies as the threshold number of common target diseases (drugs) is increased. The corresponding projections built from randomized versions of the original bipartite networks are considered to evaluate the differences. The heterogeneity of association at group level between active ingredients and diseases is evaluated in terms of the Shannon entropy and algorithmic complexity, revealing that higher levels of diversity are present for diseases compared to drugs. Finally, the robustness of the original bipartite network is evaluated in terms of most-connected nodes removal (direct attack) and random removal (random failures).

Indexed as

active ingredients and diseases classificationbipartite networkdrug–disease network

Identifiers

PMID34573762
PMCPMC8466955
OpenAlexW3196940003

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.